National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 4 of 4 Research Studies DisplayedCurtis JR, Sarsour K, Napalkov P
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study.
Interstitial lung disease (ILD) is a common extra-articular condition in rheumatoid arthritis (RA), but few studies have systematically investigated its incidence and risk factors in patients receiving anti-tumor necrosis factor-alpha (anti-TNFα) agents or alternate mechanisms of action (MOAs). After examining 13,795 episodes of biologic exposure in 11,219 patients, researchers found no significant differences in the risk of ILD and its related complications between RA patients receiving anti-TNFα agents and those receiving alternate MOA agents.
AHRQ-funded; HS018517.
Citation: Curtis JR, Sarsour K, Napalkov P .
Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study.
Arthritis Res Ther 2015 Nov 11;17:319. doi: 10.1186/s13075-015-0835-7..
Keywords: Arthritis, Comparative Effectiveness, Medication, Respiratory Conditions, Risk
Uronis HE, Ekstrom MP, Currow DC
Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis.
The researchers conducted a systematic review and meta-analysis to determine whether oxygen therapy provides symptomatic relief in COPD patients with breathlessness who do not qualify currently for long-term oxygen. They concluded that continuous oxygen during exertion, but not short-burst therapy, reduced dyspnoea in mildly- and non-hypoxemic people with COPD who would not otherwise qualify for home oxygen therapy.
AHRQ-funded; HS000079.
Citation: Uronis HE, Ekstrom MP, Currow DC .
Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis.
Thorax 2015 May;70(5):492-4. doi: 10.1136/thoraxjnl-2014-205720..
Keywords: Comparative Effectiveness, Home Healthcare, Respiratory Conditions
Hajizadeh N, Goldfeld
What happens to patients with COPD with long-term oxygen treatment who receive mechanical ventilation for COPD exacerbation? A 1-year retrospective follow-up study.
This study describes outcomes for patients with chronic obstructive pulmonary disease (COPD) on long-term oxygen treatment who are admitted to an ICU for respiratory failure and receive invasive mechanical ventilation. Of the 4,791 patients, 23 percent died in the hospital, and 45 percent died in the subsequent 12 months. Also, 67 percent of patients were readmitted at least once in the subsequent 12 months.
AHRQ-funded; HS019473.
Citation: Hajizadeh N, Goldfeld .
What happens to patients with COPD with long-term oxygen treatment who receive mechanical ventilation for COPD exacerbation? A 1-year retrospective follow-up study.
Thorax 2015 Mar;70(3):294-6. doi: 10.1136/thoraxjnl-2014-205248..
Keywords: Patient-Centered Outcomes Research, Outcomes, Comparative Effectiveness, Respiratory Conditions
Kaplan RM, Sun Q, Ries AL
AHRQ Author: Kaplan RM
Quality of well-being outcomes in the National Emphysema Treatment Trial.
The purpose of this article is to report outcomes from the National Emphysema Treatment Trial (NETT) using an index that combines quality and quantity of life. Results showed that, compared with maximal medical therapy alone, patients undergoing maximal medical therapy plus lung volume reduction surgery experienced improved health-related quality of life and gained more quality-adjusted life years.
AHRQ-authored.
Citation: Kaplan RM, Sun Q, Ries AL .
Quality of well-being outcomes in the National Emphysema Treatment Trial.
Chest 2015 Feb;147(2):377-87. doi: 10.1378/chest.14-0528.
.
.
Keywords: Comparative Effectiveness, Patient-Centered Outcomes Research, Quality of Life, Respiratory Conditions, Surgery